Safety and efficacy of GSK2248761, a next-generation nonnucleoside reverse transcriptase inhibitor, in treatment-naive HIV-1-infected subjects

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 5, 2012, Pages 2570-2575

  Zala, Carlos ^a   St Clair, Marty ^b   Dudas, Kathleen ^b   Kim, Joseph ^b   Lou, Yu ^b   White, Scott ^b   Piscitelli, Steve ^b   Dumont, Etienne ^b   Pietropaolo, Keith ^c   Zhou, Xiao Jian ^c   Mayers, Douglas ^c  

^a Hospital Privado Modelo   (Argentina)

^b GLAXOSMITHKLINE   (United States)

^c Idenix Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOSDEVIRINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PLACEBO;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; FEMALE; GENOTYPE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; MALE; MONOTHERAPY; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BINDING; RANDOMIZED CONTROLLED TRIAL; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE;

ADULT; ANTI-HIV AGENTS; ARGENTINA; BENZOXAZINES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; DRUG TOXICITY; FEMALE; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; INDOLES; MALE; MUTATION; PHOSPHINIC ACIDS; PLACEBOS; REVERSE TRANSCRIPTASE INHIBITORS; VIRAL LOAD;

EID: 84860159987     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05597-11     Document Type: Article

References (4)

1. Department of Health and Human Services. 10 January 2011. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. http://www.aidsinfo.nih.gov/ ContentFiles/AdultandAdolescentGL.pdf.
2. Goodman DD, et al. 2011. Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapy. AIDS 25:325-333.
3. WHO. 2006. Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach, 2006 revision. World Health Organization, Geneva, Switzerland. http://www.who.int/hiv/pub/guidelines/ artadultguidelines.pdf.
4. Zhou X-J, et al. 2009. Single-dose escalation and multiple-dose safety, tolerability, and pharmacokinetics of IDX899, a candidate human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitor, in healthy subjects. Antimicrob. Agents Chemother. 53:1739-1746.